Updated:
Centauri Therapeutics Limited
Centauri Therapeutics is an immunotherapy company focused on infectious diseases and oncology. The company uses its proprietary Alphamer technology to treat...
Overview
Centauri Therapeutics is an immunotherapy company focused on infectious diseases and oncology. The company uses its proprietary Alphamer technology to treat life-threatening diseases. Centauri has received funding from various sources, including the AMR Action Fund and CARB-X, to support the progression of its lead clinical candidate.
General information
Location
Region
Europe
Country
United Kingdom
City
Alderley Park, Cheshire
Corporate office
Alderley Park, Nether Alderley, Cheshire SK10 4TG, United Kingdom
Principals
Jennifer Schneider
Team Member (PhD, MPH)
Helen Bright
Team Member (PhD, FRSM)
Debra Barker
Team Member (MD, MSc)
Samantha Macro
Team Member (PhD, MCA, MBA)
Hassan Al-Bewani
Team Member (PhD)
Antonia Atkinson
Team Member
Jessica Boyle
Team Member (PhD, MBA)
Matthew Bushdyhan
Team Member (MRes)
David Chapman
Team Member (PhD)
Zenobia D’Costa
Team Member (PhD)
Iman Hassanally
Strategy and Corporate Development Manager
Daniel Hynes
Team Member (BSc)
Adam Johnson
Team Member (PhD)
Lydia Jones
Team Member (PhD)
Khushi Khare
Team Member
Jaya Saini
Team Member (PhD)
Sector focus
Frequently asked questions
How does Centauri Therapeutics source its funding?
The firm raises capital through venture rounds and non-dilutive grants. In February 2026, it extended its Series A to £30M with a £6M investment from the AMR Action Fund. It also receives grant funding from CARB-X, including a $5.1M award in July 2025 (per firm press releases).
Which sectors does Centauri explicitly avoid?
Centauri's public focus is limited to infectious diseases and oncology. The firm has not disclosed any sectors it explicitly avoids, but based on its pipeline and press releases, it does not appear active in areas such as gene therapy, rare diseases, or medical devices.
What regulatory milestones has Centauri achieved?
Centauri's lead candidate CTX-187 received FDA Qualified Infectious Disease Product (QIDP) designation in March 2026, which provides expedited development and regulatory pathways (per firm press release, March 2026).
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: